SYRS announced that the FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression as detected by an FDA approved test in ad...查看全文
产业链观察2023-12-06 20:33
#药闻简讯# 2023 年 12 月 6 日,致力于推进血液恶性肿瘤一线治疗的新护理标准生物制药公司$Syros医药(SYRS)$ 今天宣布了来自其正在进行的 SELECT- 的强有力且令人鼓舞的初步数据 AML-1 2 期试验评估他米巴罗汀(一种口服选择性视黄酸受体 α (RARα) 激动剂)与维奈托克和阿扎胞苷联合治疗新诊断...查看全文
Syros(SYRS)04-13 04:35
$Syros(SYRS)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094755 Act: 34 Size: 1 MB 网页链接查看全文
Syros(SYRS)04-06 04:35
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-042289 Size: 4 KB 网页链接查看全文
Syros(SYRS)04-03 04:25
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000207 Act: 33 Size: 4 KB 网页链接查看全文
Syros(SYRS)04-03 05:05
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040308 Size: 12 KB 网页链接查看全文
Syros(SYRS)04-03 05:05
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040320 Size: 12 KB 网页链接查看全文
Syros(SYRS)04-03 05:05
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040302 Size: 14 KB 网页链接查看全文
智通财经APP获悉,因塞特(INCY.US)已经终止了与Syros Pharmaceuticals(SYRS.US)在骨髓增生性肿瘤治疗方面的发现和研究合作。终止协议将在8月9日起60天内生效。 2018年1月,因塞特和Syros Pharmaceuticals首次签署了一项合作协议。作为合... 网页链接
$Syros(SYRS)$ PRE 14A Other preliminary proxy statements Accession Number: 0001193125-24-094755 Act: 34 Size: 1 MB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-042289 Size: 4 KB 网页链接
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000211 Act: 33 Size: 4 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040289 Size: 12 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040297 Size: 8 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040302 Size: 14 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040308 Size: 12 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040320 Size: 12 KB 网页链接
$Syros(SYRS)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-040282 Size: 12 KB 网页链接
$Syros(SYRS)$ 144 Report of proposed sale of securities Accession Number: 0001973141-24-000207 Act: 33 Size: 4 KB 网页链接